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-9-[2-hydroxy-3-nonyl]adenine) is a well-
known inhibitor of adenosine deaminase. Recently, EHNA
was shown to block the activity of purified soluble cGMP-
stimulated phosphodiesterase (PDE2) from frog, human,
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), we have examined the ef-
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M) without modification of the current-voltage or inacti-










M), and the two effects were not additive.
The effect of EHNA was not a result of adenosine deami-









other adenosine deaminase inhibitor with no effect on









absence of intracellular GTP, the substrate of guanylyl cy-




. However, under similar









. As opposed to human cardio-














 is controlled by PDE2 activity in human atrial myocytes.
Both PDE2 and PDE3 may contribute to keep the cyclic nu-
cleotides concentrations at minimum in the absence of ade-


































Hormonal regulation of cardiac function often involves a mod-
ification of adenylyl or guanylyl cyclase activity, which leads to
changes in the intracellular cAMP or cGMP concentrations
and to subsequent alterations in the degree of cAMP- or cGMP-
dependent protein phosphorylation. One of the best illustrated




















tion (1–3). However, the intracellular concentration of cyclic
nucleotides is not only regulated at the level of synthesis but
also at the level of degradation. The latter is accounted for by
cyclic nucleotide phosphodiesterases (PDEs), which break









tively, and thereby limit the degree of protein phosphorylation
(4). Like adenylyl and guanylyl cyclases, PDEs are potential
targets for hormonal regulation (4, 5). Four different PDEs




































 by the different PDEs have provided information
about the functional importance of PDE2, PDE3, and PDE4.
Inhibitors of PDE3 (e.g., milrinone) or PDE4 (e.g., rolipram,









nist isoprenaline (7, 8). In human atrial cells, PDE3 inhibition




 even in the absence of a prestimu-
lation with isoprenaline suggesting a higher basal adenylyl cy-
clase activity in this tissue (9). PDE3 inhibition can also be
achieved via intracellular cGMP perfusion (in guinea pig ven-
tricular myocytes [8, 10], but not in rat [11] or frog ventricular
myocytes [12, 13]), or via activation of guanylyl cyclase by ni-





 (for review see reference 15). Until now, however,





been resolved in frog ventricular cells. In this preparation, in-
tracellular application of cGMP reduces isoprenaline- or
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dependent PDE; PDE2, cGMP-stimulated PDE; PDE3, cGMP-inhib-






, cAMP-specific PDE; NO, nitric oxide.
 
 

















 that has been prestimulated by the nonhydrolyzable cAMP
analogue 8Br-cAMP (12, 13, 15). However, the absence of a
selective inhibitor of PDE2 has so far limited our knowledge
of its functional role in the heart, particularly in humans.





9-[2-hydroxy-3-nonyl]adenine), has been described in frog
(16), pig, and human myocardium (17). This adenine deriva-
tive was initially designed to inhibit adenosine deaminase ac-
tivity (18), which it does in the nanomolar range of concentra-
tions. However, EHNA exerts several biochemical effects that
are not readily explained on the basis of adenosine deaminase
inhibition (see references in 17). Interestingly, EHNA inhibits








M but does not significantly affect other cardiac PDE iso-




M (16, 17). Inhibi-
tory effects of EHNA on PDE2 activity have also been ob-
tained in a number of noncardiac cells, such as thymocytes
(19), vascular endothelial (20) and smooth muscle cells (21),
and PC12 cells (21). Although the classical inhibitory effect of
EHNA on adenosine deaminase limits the selectivity of the
drug with respect to PDE2, this compound has already proven
to be a useful tool in investigating the role of PDE2 in various
cell functions. For instance, inhibition of PDE2 by EHNA re-
duces the permeability of porcine pulmonary artery endothe-
lial cells (20), attenuates the cAMP metabolism changes that
follow the ligation of the T cell antigen receptor in murine thy-
mocytes (19), or reduces the pulmonary vasoconstriction that
follows a hypoxic challenge in the perfused rat lung (21). In the
heart, the most recognized effect of EHNA is to behave as a
cardioprotective agent against ischemia/reperfusion injury (for
review see reference 22). This effect is generally attributed to
the inhibition of adenosine deaminase, leading to an increase
in adenosine levels and/or to a decrease in the generation of
free radicals (23). However, EHNA also inhibits PDE2 activ-
ity in intact isolated cardiac myocytes, and, by doing so, antag-
onizes those effects of NO donors or cGMP that are mediated
by this enzyme (16). For instance, in frog ventricular myocytes,
EHNA fully reverses the inhibitory effect of the NO donors






Little is known about the role of cGMP and the presence of
its putative targets in the human heart. However, cGMP might
be involved in the development of certain cardiac pathologies.
For instance, in dilated cardiomyopathies, an increased synthe-
sis of the atrial natriuretic peptide (ANP) and NO has been
shown, and both substances activate cGMP production (24–





 in human atrial myocytes, and that this effect
was likely mediated by a cGMP inhibition of PDE3 (9). To





 in this preparation, we have now examined the effects of
EHNA on the L-type calcium current in whole-cell patch-






All protocols for obtaining human cardiac tissue were ap-
proved by the ethics committee of our institution (Groupe de Réflex-
ion sur l’Ethique Biomédicale de Bicêtre, Hôpital de Bicêtre, Univer-
sité de Paris-Sud). Specimens of right atrial appendages were obtained
from 53 patients (aged 4–79 yr) undergoing heart surgery for congen-
 
ital defects, coronary artery diseases, or valve replacement at the
Hôpital Marie-Lannelongue (Le Plessis-Robinson, France). Most pa-





-adrenergic antagonists, diuretics, ACE inhibitors, NO do-
nors, and/or antiarrhythmic drugs). In addition, all patients received
sedatives, anesthesia, and antibiotics. 14 patients had no treatment
known to possess cardiovascular effects. However, we found no obvi-





 of the drugs tested here and the therapy received (if any) by the pa-
tient. Dissociation of the cells was realized immediately after surgery.
 
Human atrial cell dissociation.
 
Myocytes were isolated as described
previously (9, 27) with some modifications. Briefly, after the excision
of the atrial tissue, the tissue was cut up and washed in a calcium-free
Tyrode solution supplemented with 30 mM 2,3-butanedionemonox-
ine for 10 min and then incubated in the same solution containing
40 IU/ml of collagenase, 15 IU/ml of protease, and 5 mg/ml of BSA
for 30 min. The solution was then replaced by fresh enzymatic solu-
tion containing only collagenase for 15–60 min until a satisfactory cell













. The cell suspension was fil-
tered and centrifuged, and the pellet was resuspended in DME sup-
plemented with 10% FCS, nonessential amino acids, 1 nM insulin,









l of this cell suspension was
put in a petri dish containing control external solution.
 
Rat ventricular and atrial cell dissociation.
 
Rat cardiomyocytes were
obtained by retrograde perfusion from hearts of male Wistar rats
(180–220 g) as described previously (28) with slight modifications.
Briefly, the rats were subjected to anesthesia by intraperitoneal injec-
tion of urethane and hearts were excised rapidly. The ionic composi-
tion of the solutions were as follows: Ca-free Tyrode solution (mM):





















-glucose 11.7; taurine 20; pH adjusted to 7.1 with NaOH
at room temperature. For enzymatic dissociation, 1 mg/ml collage-





EGTA were added to the Ca-free solution, and the free Ca concen-




M. The hearts were perfused retro-




C by an oxygenated
Ca-free Tyrode solution during 5 min followed by 1 h of perfusion at
4 ml/min with the same solution containing collagenase. The ventri-
cles and atria were then separated. Ventricles were chopped finely
and agitated gently to dissociate individual cells. The resulting cell
suspension was filtered and the cells were settled down. The superna-
tant was discarded and cells resuspended four more times in Tyrode
solution containing a progressively increasing calcium concentration.





oxygenated solution containing collagenase (0.178 IU/ml), protease
(1.06 IU/ml), and BSA (1 mg/ml) with continuous gentle agitation.
After 20 min, the cells were settled down and the supernatant was re-
moved. The cells were then resuspended as described above for ven-









The whole-cell configuration of











-tolerant human atrial and rat ventricu-
lar and atrial myocytes. In the routine protocols, the cells were depo-




80 mV to 0 mV for 200




50 mV. The prepulse, to-




M), was used to
eliminate fast sodium currents. In some experiments all sodium ions
were substituted for tetraethylammonium ions to prevent sodium
currents, without any detectable incidence on the results compared to






















). For the determination

















), a double-pulse voltage-clamp protocol was















50 mV for 10 ms, different poten-












50 mV for 3









were generated by a challenger/09-VM programmable function gen-
erator (Kinetic Software, Atlanta, GA). The cells were voltage-
clamped using a patch-clamp amplifier (model RK-400; Bio-Logic,
Claix, France). Currents were sampled at a frequency of 10 kHz using
a 12-bit analog-to-digital converter (DT2827; Data Translation, Marl-
boro, MA) connected to a PC compatible computer (386/33 System-
pro; Compaq Computer Corp., Houston, TX). All experiments were








Control external solution contained (mM): 107.1 NaCl,

























-glucose, 5 sodium pyruvate, 0.03 tetrodotoxin, pH 7.4, adjusted
with NaOH. TEA external solution consisted of (mM): 136.9 TEACl,












, pH 7.4, adjusted with
TEAOH. Control or drug-containing solutions were applied to the














electrodes (0.8–1.5 MV) were filled with control internal solution that
contained (mM): 119.8 CsCl, 5 EGTA (acid form), 4 MgCl2, 5 creatine
phosphate disodium salt, 3.1 Na2ATP, 0.42 Na2-GTP, 10 Hepes, 62
mM CaCl2 (pCa 8.5), pH 7.3, adjusted with CsOH. In some experi-
ments (see Fig. 5), a 0-GTP–containing internal solution was used
which was obtained by simply omitting Na2-GTP from the control in-
ternal solution. A change in the intracellular solution (see Fig. 6) was
made possible by the use of a perfusion system that allowed us to
modify the solution at the tip of the patch electrode during the course
of a whole-cell patch-clamp recording (12, 13).
Materials. Collagenase type IV and protease type XXIV used for
human atrial cell dissociation were purchased from Sigma (L’Isle
d’Abeau Chesnes, France). Collagenase type A for rat cardiac myo-
cyte dissociation and FCS were from Boehringer Mannheim. DME
was obtained from GIBCO-BRL (Gaithersburg, MD). 29-deoxyco-
formycin (DCF) was from Parke-Davis (Ann Arbor, MI). Tetrodo-
toxin was from Latoxan (Rosans, France). All other drugs, including
EHNA, were from Sigma. All drugs were dissolved in ionic aqueous
solutions.
Data analysis. The maximal amplitude of ICa was measured as the
difference between the peak inward current and the leak current
(I400), which was the current amplitude at the end of the 400-ms dura-
tion pulse (9). Currents were not compensated for capacitive and leak
currents. Cell membrane capacitance and series resistances were
measured by exponential analysis of current responses to 1-mV step
changes in membrane potential. Membrane capacitance was 59.664.6
pF (mean6SEM) and series resistance was 4.360.6 MV for human
atrial cells (n 5 28), 174.768.9 pF and 4.660.4 MV for rat ventricular
cells (n 5 24), and 46.164.9 pF and 6.560.7 MV for rat atrial cells
(n 5 10). The on-line analysis was made possible by programming a
PC compatible computer in Pascal language to determine each depo-
larization, peak, and steady state current value.
The results are expressed as mean6SEM. In each experimental
condition, the effects of the drugs tested on ICa are expressed as per-
cent change with respect to the values of the current under basal con-
ditions, i.e., in the absence of any hormonal stimulation. The varia-
tions in ICa induced by EHNA were tested for statistical significance
by Student’s t test.
Results
ICa was recorded in human atrial myocytes using the whole-cell
configuration of the patch-clamp technique (29). Basal ICa am-
plitude was measured 3–15 min after patch break to allow for
equilibration between intracellular and pipette solutions.
Basal ICa amplitude at 0 mV membrane potential was on aver-
age 160.2618.2 pA and ICa density, which represents the ratio
of ICa amplitude to membrane capacitance, was 2.6760.28 pA/
pF (n 5 28). As in our previous study (9), ICa densities showed
a large scatter between different patients and between individ-
ual cells from the same patient, with no obvious correlation
with the diagnosis, sex, age, or pretreatment of the patients.
Fig. 1 shows an experiment in which three different concentra-
tions of EHNA (0.1, 0.3, and 1 mM) were tested on a human
atrial myocyte. EHNA was applied extracellularly and ICa am-
plitude was measured at 0 mV membrane potential. As shown
in Fig. 1 B, application of 0.1 mM EHNA produced a strong
(70%) stimulation of basal ICa amplitude. When a threefold
higher concentration (0.3 mM) was applied, ICa almost doubled
in amplitude compared to its control value. The stimulatory ef-
fect of EHNA was completely and quickly reversible upon
washout of the drug. After ICa returned to control level, the
cell was challenged again with a third concentration (1 mM) of
EHNA, which produced a second large and reversible increase
in ICa. The individual current traces in Fig. 1 A show that the
stimulatory effect of EHNA was not accompanied by any sig-
nificant modification in the kinetics of ICa. This suggests that
EHNA did not modify the voltage dependence of the Ca chan-
nel gating. To examine this aspect further, the effect of EHNA
was investigated on the ICa current-voltage (Fig. 2 A) and inac-
tivation (Fig. 2 B) relationships. The U-shape of both curves
for basal ICa (open rectangles, Fig. 2, A and B), as well as their
respective positions on the voltage axis, are characteristic of
the high-threshold L-type Ca current in this preparation (9).
Figure 1. Time course of the effects of EHNA on basal ICa in an iso-
lated human atrial myocyte. Each symbol corresponds to a measure 
of ICa at 0 mV obtained every 8 s. The cell was first superfused with 
control solution and then exposed to increasing concentrations of 
EHNA (0.1, 0.3, and 1 mM) during the periods indicated by the solid 
lines. After the applications of 0.3 and 1 mM EHNA, the cell returned 
to control solution. The individual current traces shown on the upper 
part were obtained at the times indicated by the corresponding letters 
in the bottom graph. Dotted line, zero current level.
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As shown, 10 mM EHNA increased ICa by a similar amount at
every membrane potential (Fig. 2 A, filled rectangles) and did
not modify the inactivation curve of the current (Fig. 2 B).
Fig. 3 summarizes the results of several experiments per-
formed with EHNA in human atrial myocytes. At all three
concentrations tested (0.1, 1, and 10 mM), EHNA produced a
significant stimulation of ICa. For technical reasons, not all
three concentrations could be tested systematically on the
same myocytes, so that the results do not show a clear dose de-
pendency in the effects of EHNA. However, each time two
concentrations of the drug were examined in the same cell,
1 mM EHNA increased ICa to a higher level than 0.1 mM (e.g.,
see Fig. 1), and 10 mM EHNA either increased ICa further or
had no additional effect on ICa that had been increased by a
1 mM concentration of the drug. The effect of 1 mM isoprena-
line, a nonselective b-adrenergic agonist, was also examined in
these cells. Fig. 3 shows that the maximal stimulatory effect of
EHNA on ICa is comparable to that produced by a saturating
concentration of isoprenaline. Furthermore, EHNA (10 mM)
produced no additional effect on ICa which had been prestimu-
lated by isoprenaline (Fig. 3).
Since EHNA produced a similar maximal increase in ICa as
isoprenaline, and both compounds did not produce any addi-
tional effect on ICa when used simultaneously (Fig. 3), the most
likely mechanism for the stimulatory effect of EHNA on ICa is
an increase in cAMP concentration and a subsequent activa-
tion of ICa by cAMP-dependent phosphorylation. However,
since EHNA was shown to be an adenosine deaminase inhibi-
tor (18), it was necessary to examine the respective roles of
PDE2 and adenosine deaminase inhibition in the stimulatory
effect of EHNA on ICa in human atrial myocytes. To do this,
we first investigated the effect of DCF, a compound without
effect on PDE2 (17) but with an even higher adenosine deami-
nase inhibiting potency as compared to EHNA (references in
20). Since, at a 2 mM concentration, DCF was shown recently
to fully inhibit adenosine deaminase activity in isolated rabbit
cardiac myocytes (30), we used a somewhat similar concentra-
tion (3 mM) in most of our experiments. However, three other
concentrations of DCF (10 nM, and 1 and 30 mM) were tested
in two to three cells with no significant differences in results
(data not shown). In the experiment shown in Fig. 4, applica-
tion of 10 mM EHNA produced a large increase in ICa. After
washout of the drug, the current returned to control amplitude
and, a few minutes later, the cell was exposed to 3 mM DCF.
As shown, DCF had no stimulatory effect on ICa, but rather
slightly decreased the current. After washout of DCF, the cell
was challenged again with EHNA (10 mM), which was still
able to produce a clear stimulation in ICa. In a total of four
similar experiments in which EHNA (10 mM) produced a
clear stimulatory effect on ICa, 3 mM DCF reduced ICa by
15.5620.5%. The participation of adenosine deaminase in the
stimulatory effect of EHNA was further examined by investi-
gating the effect of a direct application of adenosine on ICa.
Application of adenosine did not mimic the effects of EHNA
on ICa. On the contrary, 1 and 10 mM adenosine induced erratic
Figure 2. Voltage-dependence of the stimulatory effect of EHNA on 
basal ICa in a human atrial myocyte. Current-voltage relationship (A) 
and inactivation curve of ICa (B) in control condition (open rectan-
gles) and in the presence of 10 mM of EHNA (filled rectangles). Inac-
tivation curves were obtained using the double-pulse protocol as indi-
cated in the inset (see also Methods).
Figure 3. Summary of the effects of EHNA on basal ICa in human 
atrial myocytes. The effects of 0.1, 1, and 10 mM of EHNA are shown 
on basal ICa and compared to the effect of 1 mM isoprenaline. The ef-
fect of 10 mM EHNA in the presence of isoprenaline is also shown. 
The bars indicate the means and the lines the SEM of the number of 
experiments indicated near the bars. Statistical significant differences 
from control ICa amplitude, **P , 0.05; ***P , 0.005.
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variations in ICa which did not reach statistical significance
(1 mM adenosine: 115.6628.6%, n 5 8; 10 mM adenosine:
217.364.1%, n 5 4). Thus, inhibition of adenosine deaminase
is unlikely to participate in the stimulatory effect of EHNA
on ICa.
These results suggest that EHNA may affect ICa through its
inhibitory effect on PDE2 (16, 17). Since PDE2 may hydrolyze
both cAMP and cGMP, and its activity is stimulated by low
concentrations of cGMP binding to an allosteric site (4), we
tested the possibility that a basal production of cGMP is re-
sponsible for a meaningful PDE2 activity in human atrial myo-
cytes. Guanylyl cyclases synthesize cGMP from GTP, with a
Km of 100–150 mM (31, 32). Thus, elimination of GTP from the
intracellular solution should abolish, or at least diminish, en-
dogenous cGMP production. Such an approach was already
used in human atrial cells to examine the role of guanylyl cy-
clase activity in the effect of the atrial natriuretic peptide on ICa
(33). Therefore, we reexamined the effect of EHNA on ICa in
human atrial myocytes in the absence of GTP in the patch pi-
pette solution. In 5 out of 27 cells without intracellular GTP, 10
mM EHNA produced either no effect or a small increase in ICa
that did not reach statistical significance (Fig. 5). However, in
the remaining 22 cells, EHNA (10 mM) always reduced ICa
(Fig. 5). We verified that the capacity of EHNA to stimulate
ICa in the presence of a routine (420 mM) GTP concentration
was preserved in the same series of experiments (Fig. 5). It
should be noted that the absence of GTP in the dialyzing solu-
tion did not reduce the GTP concentration, at least near the
membrane, to a sufficient extent to blunt the receptor-medi-
ated activation of GTP-binding proteins. Indeed, even in the
absence of exogenous GTP, isoprenaline (1 mM) was still able
to produce a strong stimulation of ICa (Fig. 5). This was not un-
expected since the Km of G proteins for GTP is z 0.3 mM (34),
i.e., almost three orders of magnitude lower than that of gua-
nylyl cyclases (31, 32).
The above results demonstrate that GTP is required to sup-
port a basal activity of PDE2. The most likely explanation for
this is that GTP is converted to cGMP, which then stimulates
PDE2 activity. However, we have shown earlier that basal ICa
is also controlled by PDE3, a cGMP-inhibited PDE, in human
atrial myocytes (9). So, an obvious question is: What are the
respective contributions of PDE2 and PDE3 in the control of
ICa when cGMP level rises inside the cell? To address this
question, we examined the effect of an intracellular perfusion
with cGMP in human atrial myocytes. The myocytes were dia-
lyzed with a 0 GTP–containing internal solution in order to
abolish basal cGMP production by the cells. As shown in Fig.
6, intracellular perfusion of a human atrial myocyte with 0.5
mM cGMP produced a net stimulation of basal ICa. The stimu-
latory effect of cGMP on ICa was fully reversible when the pi-
pette solution returned to the initial 0 GTP–containing inter-
nal solution. The stimulatory effect of cGMP was smaller in
amplitude than the effect of 50 mM cAMP, which produced an
approximately twofold increase in ICa (Fig. 6). The effect of 0.5
mM cGMP was examined in a total of 12 similar experiments,
as in Fig. 6. In these cells, cGMP increased basal ICa by
80.0615.5%. Five of these cells survived a second challenge
with 50 mM intracellular cAMP which enhanced ICa by
209.1665.4% over its basal amplitude. Thus, cGMP inhibition
of PDE3 appears to dominate over cGMP stimulation of
PDE2 when exogenous cGMP was introduced in the cyto-
plasm.
The findings that EHNA and cGMP stimulate basal ICa in
human atrial myocytes are somewhat at variance with our ear-
lier findings that cGMP and EHNA have no effect on basal ICa
in frog ventricular myocytes. On the contrary, cGMP strongly
antagonized the stimulatory effect of isoprenaline or cAMP on
ICa (3, 12, 13, 15) in this preparation, and this effect was medi-
ated by PDE2 activation since it was reversed by EHNA (16).
To examine whether these differences were a result of tissue
Figure 4. Comparative effects of EHNA and DCF on basal ICa in a 
human atrial myocyte. Each symbol corresponds to a measure of ICa 
at 0 mV obtained every 8 s. The cell was first superfused with control 
solution and then exposed to EHNA (10 mM) or DCF (3 mM) during 
the periods indicated by the solid lines.
Figure 5. Summary of the effects of EHNA in the absence and pres-
ence of intracellular GTP on basal ICa in human atrial myocytes. The 
effects of 0.1 mM of EHNA (filled bars) were examined in human 
atrial myocytes that were dialyzed with a patch pipette solution that 
contained either no GTP (0 GTP) or 420 mM GTP (see Methods). 
The data obtained in 0 GTP were divided in experiments that showed 
either inhibitory effects (22 cells) or stimulatory effects (5 cells) of 
EHNA. These data are compared with the effect of 1 mM isoprena-
line (open bar). The bars indicate the means and the lines the SEM of 
the number of experiments indicated near the bars.
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(atrium versus ventricle) or species (mammalian versus am-
phibian) differences, we have examined the effect of EHNA
on basal ICa in rat ventricular and atrial myocytes. Rat ventric-
ular cells were larger in size than human atrial myocytes and
had a threefold higher membrane capacitance (174.768.9 pF,
n 5 24, versus 59.664.6 pF, n 5 28). Under basal conditions,
the mean ICa amplitude in rat ventricular myocytes was
915.6642.8 pA corresponding to a mean current density of
5.660.5 pA/pF. On the contrary, rat atrial myocytes were
somewhat smaller in size than human atrial myocytes and had
a slightly lower membrane capacitance (46.164.9 pF, n 5 10).
Basal ICa amplitude in rat atrial myocytes averaged 127.1629.1
pA, corresponding to a mean current density of 2.760.5 pA/pF
(n 5 10). Fig. 7 A shows a typical experiment performed in a
rat ventricular myocyte. Three increasing concentrations of
EHNA (0.1, 1, and 10 mM) were successively tested on the myo-
cyte. As shown, none of the concentrations produced any sig-
nificant effect on ICa. Unlike EHNA, application of 1 mM iso-
prenaline produced a clear stimulation of the current (Fig. 7
A). Fig. 7 B summarizes the results of several similar experi-
ments and shows that none of the three concentrations of
EHNA produced a significant effect on basal ICa in rat ventric-
ular myocytes. Intracellular perfusion with cGMP was also
shown earlier to have no effect on basal ICa in this preparation
(11). On the contrary, isoprenaline (0.1 and 1 mM) produced a
clear increase in ICa in these cells. However, as shown in Fig. 7 B,
application of EHNA (10 mM) to the rat ventricular myocytes
in the presence of an intermediate (0.1 mM) or saturating
(1 mM) concentration of isoprenaline also had no effect on ICa.
The absence of effect of EHNA on basal ICa in rat ventricular
myocytes as compared to human atrial myocytes was not be-
cause of a tissue difference since EHNA had also no effect on
basal ICa in rat atrial myocytes. Indeed, in the presence of 10
and 30 mM EHNA, ICa amplitude in rat atrial myocytes was
96.666.2% (n 5 3) and 92.863.0% (n 5 7) of its basal ampli-
tude, respectively, while 0.1 and 10 mM isoprenaline increased
Figure 6. Effects of cGMP and cAMP on basal ICa in human atrial 
myocytes. Each symbol corresponds to a measure of ICa at 0 mV ob-
tained every 8 s. The cell was superfused with control solution 
throughout the entire experiment. The cell was initially dialyzed with 
a 0 GTP–containing internal solution. At the first arrow, the pipette 
solution was changed to one containing 0.5 mM cGMP which pro-
duced a clear increase in ICa. At the second arrow, the pipette solu-
tion returned to the initial 0-GTP solution. At the third arrow, 50 mM 
cAMP was added to the pipette solution which started to dialyze the 
cell. This produced a large increase in ICa that was reversed when the 
pipette solution returned to initial 0-GTP solution (last arrow). The 
individual current traces shown on the upper part were obtained at 
the times indicated by the corresponding letters in the bottom graph. 
Dotted line, zero current level.
Figure 7. Effects of EHNA and isoprenaline on basal ICa in rat ven-
tricular myocytes. (A) Each symbol corresponds to a measure of ICa 
at 0 mV obtained every 8 s in a rat ventricular myocyte. The cell was 
first superfused with control solution and then exposed to increasing 
concentrations of EHNA (0.1, 1, and 10 mM) or to isoprenaline
(1 mM) during the periods indicated by the solid lines. (B) Summary 
of the effects of 0.1, 1, and 10 mM EHNA, of 0.1 and 1 mM isoprena-
line in the absence and presence of 10 mM EHNA on basal ICa in rat 
ventricular myocytes. The bars indicate the mean values and the con-
tinuous lines the SEM of the number of experiments indicated near 
the bars.
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the current by 65.3622.6% (n 5 4) and 96.7627.2% (n 5 4),
respectively.
Discussion
In this study, we examined the effects of EHNA on the high-
threshold calcium current (ICa) in human atrial myocytes and
in rat atrial and ventricular myocytes. Several main conclu-
sions can be drawn from our experiments: (a) EHNA pro-
duces a stimulation of basal ICa in human atrial myocytes with
no modification in the voltage dependence of the Ca current;
(b) the maximal stimulatory effect of EHNA on ICa is compa-
rable in amplitude to the maximal effect of isoprenaline, and
the two effects are not additive; (c) the effect of EHNA is not a
result of adenosine deaminase inhibition; (d) this effect re-
quires the presence of intracellular GTP; (e) intracellular ap-
plication of cGMP produces a stimulation of ICa; and (f) the
stimulatory effect of EHNA on basal ICa is not present in rat
atrial and ventricular myocytes. We conclude that basal cal-
cium current is controlled by PDE2 activity in human atrial
myocytes. The requirement of GTP, the substrate of guanylyl
cyclase, for the effect of EHNA, also suggests the presence of a
significant basal activity of guanylyl cyclase in these cells.
Since the discovery by Beavo et al. (35) of a stimulatory ef-
fect of cGMP on cAMP hydrolysis in various tissues including
heart, a lot of information has accumulated on the properties,
structure, and amino acid sequence of PDE2 (for review see
reference 4). However, although PDE2 is expressed in cardiac
myocytes (4, 6), relatively little is known on its function. One
reason for this is that, until recently, no agent had been de-
scribed as a selective inhibitor of PDE2 (4, 6). The recent find-
ings that EHNA inhibits selectively PDE2 isoform, as far as
the soluble PDE isoforms are concerned, in cardiac myocytes
(16, 17) as well as in other preparations (19–21), opened up the
possibility to directly examine the role of this enzyme in the
heart. Thus, in this study, we used EHNA to demonstrate a
participation of PDE2 in the regulation of basal L-type Ca cur-
rent in human atrial myocytes.
However, a major drawback in the use of EHNA is that
this compound is also a potent inhibitor of adenosine deami-
nase (18). This raises the possibility that inhibition of adeno-
sine deaminase, possibly via an accumulation of adenosine, may
participate in the effects of EHNA. However, for several rea-
sons, we believe that this hypothesis is unlikely. First, adeno-
sine did not mimic the effects of EHNA on basal ICa in our ex-
perimental conditions. Moreover, a recent study showed that
extracellular application of adenosine inhibits basal ICa in hu-
man atrial myocytes (36). This effect is likely mediated by the
activation of A1-adenosine receptors which are negatively
coupled to adenylyl cyclase. The intracellular accumulation of
adenosine upon exposure to EHNA might also affect the regu-
lation of ICa. In particular, adenosine could inhibit adenylyl cy-
clase by binding to the intracellular P-site of the enzyme. How-
ever, such an effect would result in an inhibition of ICa which
has not been observed with EHNA. Second, it is unlikely that
adenosine deaminase is functioning under our experimental
conditions, even in the absence of EHNA. Indeed, the Km of
adenosine deaminase for adenosine is in the 20–50 mM range
(37). Thus, unless adenosine deaminase activity takes place in
a compartment not readily available for intracellular perfu-
sion, e.g., in the close vicinity of the membrane, the continuous
dialysis of the cell in our whole-cell patch-clamp experiments
would prevent such a high accumulation of adenosine within
the cell. Third, the cell is also continuously superfused with
fresh extracellular solution which does not contain adenosine.
This would tend to rapidly dilute from the extracellular surface
of the membrane any adenosine that would be released by the
cell, hence eliminating a possible activation of membrane aden-
osine receptors. Finally, inhibition of adenosine deaminase by
DCF did not mimic the effect of EHNA on ICa (Fig. 4). There-
fore, we conclude that inhibition of adenosine deaminase does
not participate, to any significant extent, in the stimulatory ef-
fects of EHNA on ICa. However, we cannot completely ex-
clude the possibility that adenosine deaminase inhibition may
participate in the small inhibitory effect of EHNA observed in
the majority of human atrial myocytes perfused without GTP
(Fig. 5).
We also examined the possibility that EHNA might have
other effects in our preparation, besides the inhibitory effect
on PDE2 and adenosine deaminase, which could account for
some of the observed effects of EHNA on ICa. However, we
found that EHNA did not modify the kinetics (Fig. 1) or volt-
age dependence (Fig. 2) of ICa. In addition, EHNA exerted no
effect on ICa stimulated by isoprenaline (Fig. 3), which suggests
that EHNA does not directly interact with the Ca channels, in
their phosphorylated or nonphosphorylated states. In addition
to inhibition of adenosine deaminase and PDE2, EHNA has
been found to be an inhibitor of dynein ATPase activity, actin
assembly, and cell motility (38, 39). Although we did not ad-
dress these questions specifically, it is hard to anticipate how
these alternative mechanisms could account for the observed
effects of EHNA on ICa.
Unlike in human atrial myocytes, EHNA had no effect on
basal ICa in frog ventricular myocytes (16) and in rat ventricu-
lar and atrial myocytes (Fig. 7). This suggests that PDE2 par-
ticipates in the basal PDE activity of human atrial myocytes
but not in the other animal species tested so far. Species differ-
ences were also found for the participation of PDE3. Indeed,
we have shown previously using milrinone as a selective inhib-
itor of PDE3 that this enzyme contributes significantly to the
control of the basal amplitude of ICa in human (9) but not in
frog (7, 40) cardiac myocytes. Thus, in human atrial myocytes,
PDE2 and PDE3 participate in the basal PDE activity in-
volved in the regulation of ICa. Both enzymes are necessary to
maintain low cAMP concentration, since inhibition of one
PDE leads to a large increase in basal ICa. An interesting ob-
servation comes from our experiments with intracellular appli-
cation of cGMP. At the cGMP concentration used (0.5 mM),
PDE3 should be fully inhibited and PDE2 substantially acti-
vated (4). However, ICa increased strongly under these condi-
tions (Fig. 6) indicating that cGMP inhibition of PDE3 domi-
nated over cGMP stimulation of PDE2. In other words,
cGMP-stimulated PDE2 was insufficient to hydrolyze the
basal production of cAMP in human atrial cells when PDE3
was inhibited. This situation is somewhat similar to that found
recently in guinea pig ventricular myocytes. In this prepara-
tion, intracellular application of cGMP enhanced basal (10) as
well as isoprenaline-stimulated ICa (8, 10), and this effect was
attributed to PDE3 inhibition (8, 10). However, this result is at
variance with what was found in frog and rat myocytes. In-
deed, in both preparations, intracellular perfusion with cGMP
had no effect on basal ICa (3, 12, 13, 15). Moreover, cGMP per-
fusion induced a dramatic inhibitory effect on isoprenaline- or
cAMP-stimulated ICa in both preparations (12, 13). In frog, this
PDE2 Regulates Human Cardiac Ca Current 2717
effect was because of PDE2 activation since it was antagonized
by EHNA (16). However, in rat, this effect was because of ac-
tivation of cGMP-dependent protein kinase (PKG, 11). PKG
also mediated the inhibitory effect of cGMP found in guinea
pig myocytes when higher concentrations of cGMP were used,
or when PDE3 was blocked by milrinone or IBMX (8, 10, 41).
These large differences between different animal species in the
effect of cGMP and of PDE2 and PDE3 inhibitors on basal
and stimulated ICa allowed us to propose in each species a rela-
tive order of potency of the three cGMP targets with respect to
their modulation of ICa: PDE2 . PDE3 .. PKG in frog (7, 12,
13); PDE3 . PKG .. PDE2 in guinea pig (8, 10, 41); PKG .
PDE3 .. PDE2 in rat (11, 15); PDE3 . PDE2 . PKG in hu-
man (9, this study). Further experiments are needed to delin-
eate whether these species differences are a result of differ-
ences in protein expression, substrate specificity, maximal
enzymatic activity, and/or intracellular localization of the three
cGMP-binding proteins. Moreover, at basal, the respective
role of each enzyme will also depend on the basal activity of
adenylyl cyclase and/or guanylyl cyclase. Interestingly, we
found that the stimulatory effect of EHNA disappeared in the
absence of intracellular GTP (Fig. 5) suggesting that the activ-
ity of PDE2 in human atrial myocytes is itself controlled by the
activity of guanylyl cyclase.
It is likely that the respective activities of PDE2 and PDE3
and their localization within the cell will determine the re-
sponse of the cardiac muscle to various modulators of the
cGMP and cAMP cascades. In this respect, there is indirect ev-
idence that PDE2 might be involved in the muscarinic regula-
tion of ICa and contraction in rat and rabbit cardiac myocytes
(42–45) but not in guinea pig (46) and frog cardiac myocytes
(47, 48). Thus, to test this hypothesis directly, it might be inter-
esting to examine whether EHNA is able to antagonize the in-
hibitory effect of acetylcholine on ICa and contraction in these
preparations. These important species differences should also
prompt us to examine the participation of PDE2 in the musca-
rinic regulation of the human heart. Finally, the use of EHNA
should allow us to progress in our comprehension of the regu-
latory role of PDE2 in the function of other cell types and or-
gans and in their responses to various physiological stimuli.
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